Welcome to Multibagg AI
Log in to access personalized features
Investor Presentation
Q3 FY25
Investor Presentation
Q2 FY25
Investor Presentation
Q4 FY22
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY21
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY20
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Solara Active Pharma Sciences Ltd (SOLARA) is currently trading at 575.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Solara Active Pharma Sciences Limited is a major manufacturer of active pharmaceutical ingredients (APIs), operating six plants with USFDA and other global regulatory approvals. The company's ibuprofen business, once a major revenue driver, now faces significant challenges due to excess capacity and outdated processes, leading to financial strain. Despite ibuprofen struggles, Solara's non-ibuprofen business shows promise, delivering 25% EBITDA margins and high gross profitability, signaling a strategic pivot towards high-margin APIs. Solara intends to convert some facilities for multipurpose use, including high potent APIs, to mitigate ibuprofen challenges and capitalize on growing niches. The management is pursuing strategic evaluations to potentially divest or revamp the ibuprofen business, aiming for a clearer strategic direction by Q4 2026.
Over the past 52 weeks, Solara Active Pharma Sciences Ltd has traded between a low of ₹422.85 and a high of ₹734.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Solara Active Pharma Sciences Ltd has a market capitalization of approximately 2,757.51. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Solara Active Pharma Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -372.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,757.51 Cr, Solara Active Pharma Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Solara Active Pharma Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Solara Active Pharma Sciences Ltd is -372.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The provided summaries report Q1 revenue at about ₹320 crore (₹320.00 crore and ₹319.15 crore), with roughly 15% quarter-on-quarter growth.
The Q4 FY26 results are scheduled for May 2026 (expected), along with approval of audited financial statements for the quarter and full year ended March 31, 2026.
Bearish
6
Neutral
5
Bullish
3
Bearish
6
Neutral
5
Bullish
35
Bearish
0
Neutral
0
Bullish
32
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
188.75 | 2,957 Cr | 30.34 | 0.44 | 0.00 | 1.46 | 2.66 | 0.82 | ||
577.95 | 2,758 Cr | -372.13 | 2.20 | 0.00 | -0.12 | 4.81 | -0.32 | ||
48.64 | 2,665 Cr | 28.09 | 2.14 | 0.41 | 5.96 | 7.58 | 4.94 | ||
378.00 | 2,662 Cr | 10.53 | 0.98 | 0.00 | 2.88 | 3.79 | 6.77 | ||
560.00 | 2,478 Cr | 173.65 | 5.05 | 0.00 | 2.91 | 2.79 | — | ||
2338.95 | 2,424 Cr | 35.99 | 7.33 | 0.00 | 20.31 | 21.46 | 11.37 | ||
181.35 | 2,237 Cr | -45.83 | 1.87 | 0.33 | 3.03 | 3.56 | -2.06 | ||
| Median: 7 Co. | — | 378.00 | 2,662 Cr | 28.09 | 2.14 | 0.00 | 2.91 | 3.79 | 2.88 |
Solara Active Pharma Sciences Limited is a major manufacturer of active pharmaceutical ingredients (APIs), operating six plants with USFDA and other global regulatory approvals.
The company's ibuprofen business, once a major revenue driver, now faces significant challenges due to excess capacity and outdated processes, leading to financial strain.
Despite ibuprofen struggles, Solara's non-ibuprofen business shows promise, delivering 25% EBITDA margins and high gross profitability, signaling a strategic pivot towards high-margin APIs.
Solara intends to convert some facilities for multipurpose use, including high potent APIs, to mitigate ibuprofen challenges and capitalize on growing niches.
The management is pursuing strategic evaluations to potentially divest or revamp the ibuprofen business, aiming for a clearer strategic direction by Q4 2026.
Pharmaceuticals & Biotechnology
Pharmaceuticals
2,747 Cr
Low Risk
-370.7
34.1
—
2.2
734.20
422.85
Sales CAGR
Profit CAGR
ROE
ROCE
